Select Publications
Journal articles
2024, 'Connecting the changing trace elements spectrum and survival in sarcoma: a pilot study.', Metabolomics, 20, pp. 129, http://dx.doi.org/10.1007/s11306-024-02178-z
,2024, 'Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma', Cancer Epidemiology, 92, http://dx.doi.org/10.1016/j.canep.2023.102432
,2024, 'From ownership to custodianship of tumor biopsy tissue in genomic testing: A mixed methods study of patient views', Oncologist, 29, pp. e1169 - e1179, http://dx.doi.org/10.1093/oncolo/oyae074
,2024, 'HGG-50. LOW GRADE GLIOMA CAUGHT IN TRANSFORMATION: UTILITY OF COMPREHENSIVE GENOMIC PROFILING IN PEDIATRIC LI FRAUMENI SYNDROME ASSOCIATED HIGH-GRADE GLIOMA', Neuro-Oncology, 26, http://dx.doi.org/10.1093/neuonc/noae064.334
,2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.', Journal of Clinical Oncology, 42, pp. 1557 - 1557, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.1557
,2024, 'Abstract 775: Underlying germline genetic architecture of pediatric sarcomas: Evaluating the role of common and rare variants in 4,160 patients', Cancer Research, 84, pp. 775 - 775, http://dx.doi.org/10.1158/1538-7445.am2024-775
,2024, 'ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue', Future Oncology, 20, pp. 361 - 371, http://dx.doi.org/10.2217/fon-2023-0366
,2024, 'Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00453
,2024, 'Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans', Genetics in Medicine Open, 2, http://dx.doi.org/10.1016/j.gimo.2024.101895
,2024, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery (United States), http://dx.doi.org/10.1016/j.surg.2024.05.058
,2024, 'POT1 clinical risk management is an open question', European Journal of Human Genetics, http://dx.doi.org/10.1038/s41431-024-01676-x
,2024, 'When genetics and pediatric cancer collide: Understanding and optimizing families' experiences', Neuro-Oncology Advances, 6, http://dx.doi.org/10.1093/noajnl/vdae133
,2024, '636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy', Annals of Oncology, 35, pp. S505 - S505, http://dx.doi.org/10.1016/j.annonc.2024.08.703
,2023, 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature', British Journal of Haematology, 203, pp. 481 - 484, http://dx.doi.org/10.1111/bjh.19059
,2023, 'Family communication and results disclosure after germline sequencing: A mixed methods study', Patient Education and Counseling, 114, http://dx.doi.org/10.1016/j.pec.2023.107800
,2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0
,2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 2594 - 2594, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2594
,2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.', Journal of Clinical Oncology, 41, pp. 4093 - 4093, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.4093
,2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.', Journal of Clinical Oncology, 41, pp. 1540 - 1540, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1540
,2023, 'Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.', Journal of Clinical Oncology, 41, pp. 10578 - 10578, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10578
,2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.', Journal of Clinical Oncology, 41, pp. 5526 - 5526, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5526
,2023, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', Science, 379, pp. 253 - 260, http://dx.doi.org/10.1126/science.abj4784
,2022, 'Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study', Supportive Care in Cancer, 30, pp. 8201 - 8210, http://dx.doi.org/10.1007/s00520-022-07272-3
,2022, 'Validation of the Knowledge of Genome Sequencing (KOGS) scale in cancer patients', Patient Education and Counseling, 105, pp. 3110 - 3115, http://dx.doi.org/10.1016/j.pec.2022.06.009
,2022, 'Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting', European Journal of Human Genetics, 30, pp. 930 - 937, http://dx.doi.org/10.1038/s41431-022-01069-y
,2022, 'Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients', Patient Education and Counseling, 105, pp. 2206 - 2216, http://dx.doi.org/10.1016/j.pec.2022.01.011
,2022, 'Validation of the multidimensional impact of Cancer Risk Assessment Questionnaire to assess impact of waiting for genome sequencing results', Psycho-Oncology, 31, pp. 1204 - 1211, http://dx.doi.org/10.1002/pon.5908
,2022, 'Psychological predictors of cancer patients' and their relatives’ attitudes towards the return of genomic sequencing results', European Journal of Medical Genetics, 65, http://dx.doi.org/10.1016/j.ejmg.2022.104516
,2022, 'Cancer patient knowledge about and behavioral intentions after germline genome sequencing', Patient Education and Counseling, 105, pp. 707 - 718, http://dx.doi.org/10.1016/j.pec.2021.07.004
,2022, 'My Research Results: a program to facilitate return of clinically actionable genomic research findings', European Journal of Human Genetics, 30, pp. 363 - 366, http://dx.doi.org/10.1038/s41431-021-00973-z
,2022, 'Psychological predictors of advanced cancer patients’ preferences for return of results from comprehensive tumor genomic profiling', American Journal of Medical Genetics, Part A, 188, pp. 725 - 734, http://dx.doi.org/10.1002/ajmg.a.62563
,2022, 'Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients', Patient Education and Counseling, 105, pp. 452 - 459, http://dx.doi.org/10.1016/j.pec.2021.05.018
,2022, 'Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer', Genes Chromosomes and Cancer, 61, pp. 81 - 93, http://dx.doi.org/10.1002/gcc.23006
,2022, 'Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study', Journal of Genetic Counseling, 31, pp. 96 - 108, http://dx.doi.org/10.1002/jgc4.1455
,2022, 'Psychological Outcomes in Advanced Cancer Patients After Receiving Genomic Tumor Profiling Results', Health Psychology, 41, pp. 396 - 408, http://dx.doi.org/10.1037/hea0001181
,2021, 'Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology', npj Precision Oncology, 5, pp. 58, http://dx.doi.org/10.1038/s41698-021-00194-z
,2021, 'Fear of cancer recurrence in patients undergoing germline genome sequencing', Supportive Care in Cancer, 29, pp. 7289 - 7297, http://dx.doi.org/10.1007/s00520-021-06311-9
,2021, 'Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling', Psycho-Oncology, 30, pp. 1920 - 1929, http://dx.doi.org/10.1002/pon.5764
,2021, 'The experiences and needs of australian medical oncologists in integrating comprehensive genomic profiling into clinical care: A nation-wide survey', Oncotarget, 12, pp. 2169 - 2176, http://dx.doi.org/10.18632/ONCOTARGET.28076
,2021, 'Does undertaking genome sequencing prompt actual and planned lifestyle-related behavior change in cancer patients and survivors? A qualitative study', Journal of Psychosocial Oncology Research and Practice, 3, pp. E059, http://dx.doi.org/10.1097/OR9.0000000000000059
,2021, 'Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: ‘Another piece of the pie’', Journal of Genetic Counseling, 30, pp. 849 - 860, http://dx.doi.org/10.1002/jgc4.1384
,2021, 'Family communication about genomic sequencing: A qualitative study with cancer patients and relatives', Patient Education and Counseling, 104, pp. 944 - 952, http://dx.doi.org/10.1016/j.pec.2020.10.022
,2021, 'Cancer Patient Experience of Uncertainty While Waiting for Genome Sequencing Results', Frontiers in Psychology, 12, http://dx.doi.org/10.3389/fpsyg.2021.647502
,2021, 'Germline RET variants underlie a subset of paediatric osteosarcoma', Journal of Medical Genetics, 58, pp. 20 - 24, http://dx.doi.org/10.1136/jmedgenet-2019-106734
,2021, 'Heritable cancer risk in the genomic ERA', Pathology, 53, pp. S10 - S10, http://dx.doi.org/10.1016/j.pathol.2021.05.038
,2021, 'Streamlined use of protein structures in variant analysis', , http://dx.doi.org/10.1101/2021.09.10.459756
,2020, 'Author Correction: Diagnosis of fusion genes using targeted RNA sequencing (Nature Communications, (2019), 10, 1, (1388), 10.1038/s41467-019-09374-9)', Nature Communications, 11, pp. 1810, http://dx.doi.org/10.1038/s41467-020-15697-9
,2020, 'Cancer patients' views and understanding of genome sequencing: A qualitative study', Journal of Medical Genetics, 57, pp. 671 - 676, http://dx.doi.org/10.1136/jmedgenet-2019-106410
,2020, 'Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular Profiling', Translational Oncology, 13, pp. 100799, http://dx.doi.org/10.1016/j.tranon.2020.100799
,2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', Journal of Clinical Oncology, 38, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3073
,